SynthesisAdvances in nutrition (Bethesda, Md.)2024
The Effects of Bifidobacterium Probiotic Supplementation on Blood Glucose: A Systematic Review and Meta-Analysis of Animal Models and Clinical Evidence.
Synthesis in Advances in nutrition (Bethesda, Md.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Trial
- Bifidobacterium breve BBr60 Improves Metabolic Abnormalities by Regulating Gut Microbiota Balance in a High-Fat Diet-Induced Obese Mouse Model.Diabetes, obesity & metabolism · 2026Article
- Probiotics-derived postbiotics improve host metabolic syndrome by activating the adipocyte thermogenic signaling pathway in high-fat diet-fed mice.iMetaOmics · 2026Article
- Bifidobacterium longum TISTR 2893 Regulates Glycemic Homeostasis by Modulating the Hepatic Carbohydrate Metabolism in High-Fat Diet and Streptozotocin-Induced Type 2 Diabetic Rats.Probiotics and antimicrobial proteins · 2026Article
- Bifidobacterium's Influential Role in the Battle Against Obesity: Going Beyond Probiotics.Probiotics and antimicrobial proteins · 2026Review
- High Dietary Carbonyl Iron Reshapes the Gut Microbiome and Impairs Hepatic Insulin Sensitivity in a Time-Dependent Manner.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Long-term efficacy of dapagliflozin combined with Bifidobacterium triple viable tablets on metabolic syndrome and gut microbiota in overweight/obese patients with type 2 diabetes.Endocrine connections · 2025Article
- The Effect of Semaglutide on Gut Microbiota in Chinese Patients with Type 2 Diabetes Poorly Controlled by Metformin.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Gut microbiome in adult Asians with obesity, type 2 diabetes mellitus, and a combination of obesity and type 2 diabetes mellitus.Bioscience of microbiota, food and health · 2025Review
- "Protective effects of artichoke extract and Bifidobacterium longum on male infertility in diabetic rats".Biochemistry and biophysics reports · 2024Article
- Gut Microbiota Dysbiosis, Oxidative Stress, Inflammation, and Epigenetic Alterations in Metabolic Diseases.Antioxidants (Basel, Switzerland) · 2024Review
- The Effect ofNutrients · 2024Article
- Review
- Updated Insights into Probiotics and Hepatobiliary Diseases.Biomedicines · 2024Review
- The gut microbial composition in polycystic ovary syndrome with hyperandrogenemia and its association with steroid hormones.Frontiers in cell and developmental biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Probiotic supplementation is a potential therapeutic for metabolic diseases, including obesity, metabolic syndrome (MetS), and type 2 diabetes (T2D), but most studies deliver multiple species of bacteria in addition to prebiotics or oral pharmaceuticals. This may contribute to conflicting evidence in existing meta-analyses of probiotics in these populations and warrants a systematic review of the literature to assess the contribution of a single probiotic genus to better understand the contribution of individual probiotics to modulate blood glucose. We conducted a systematic review and meta-analysis of animal studies and human randomized controlled trials (RCTs) to assess the effects of Bifidobacterium (BF) probiotic supplementation on markers of glycemia. In a meta-analysis of 6 RCTs, BF supplementation had no effect on fasting blood glucose {FBG; mean difference [MD] = -1.99 mg/dL [95% confidence interval (CI): -4.84, 0.86], P = 0.13}, and there were no subgroup differences between subjects with elevated FBG concentrations and normoglycemia. However, BF supplementation reduced FBG concentrations in a meta-analysis comprised of studies utilizing animal models of obesity, MetS, or T2D [n = 16; MD = -36.11 mg/dL (CI: -49.04, -23.18), P < 0.0001]. Translational gaps from animal to human trials include paucity of research in female animals, BF supplementation in subjects that were normoglycemic, and lack of methodologic reporting regarding probiotic viability and stability. More research is necessary to assess the effects of BF supplementation in human subjects with elevated FBG concentrations. Overall, there was consistent evidence of the efficacy of BF probiotics to reduce elevated FBG concentrations in animal models but not clinical trials, suggesting that BF alone may have minimal effects on glycemic control, may be more effective when combined with multiple probiotic species, or may be more effective in conditions of hyperglycemia rather than elevated FBG concentrations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.